Ninety One (UK)
JAZZ icon

Ninety One (UK)’s Jazz Pharmaceuticals JAZZ Stock Holding History

Ninety One (UK)’s Portfolio JAZZ Stock Details JAZZ Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2016
Q3 		– Sell
-169,769
Closed -$24M – 317
2016
Q2 		$24M Sell
169,769
-2,000
-1% -$295K 0.12% 154
2016
Q1 		$22.4M Sell
171,769
-6,500
-4% -$809K 0.12% 142
2015
Q4 		$25.1M Sell
178,269
-2,189
-1% -$303K 0.14% 125
2015
Q3 		$24M Sell
180,458
-3,300
-2% -$568K 0.15% 118
2015
Q2 		$32.4M Sell
183,758
-15,699
-8% -$2.82M 0.18% 118
2015
Q1 		$34.5M Sell
199,457
-33,900
-15% -$5.82M 0.2% 114
2014
Q4 		$38.2M Sell
233,357
-7,403
-3% -$1.23M 0.23% 105
2014
Q3 		$38.7M Buy
240,760
+7,804
+3% +$1.2M 0.23% 116
2014
Q2 		$34.2M Buy
232,956
+597
+0.3% +$82.8K 0.2% 129
2014
Q1 		$32.2M Sell
232,359
-4,300
-2% -$647K 0.21% 116
2013
Q4 		$30M Sell
236,659
-106,700
-31% -$11M 0.21% 108
2013
Q3 		$31.6M Buy
343,359
+897
+0.3% +$72.4K 0.23% 110
2013
Q2 		$23.5M Buy
+342,462
New +$20.9M 0.18% 124

Other funds holding JAZZ

Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
PI
Putnam Investments Boston, Massachusetts $75.7B AUM 34.45% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Fidelity International
Fidelity International Hamilton, Bermuda $129B AUM 30.83% 1-Year Est. Return
Westfield Capital Management
Westfield Capital Management Boston, Massachusetts $23.8B AUM 49.45% 1-Year Est. Return
CCM
Cadian Capital Management New York $821M AUM 14.36% 1-Year Est. Return
Bank of New York Mellon
Bank of New York Mellon New York $544B AUM 28.31% 1-Year Est. Return
PHS
PFM Health Sciences San Francisco, California $1.1B AUM 57.92% 1-Year Est. Return
BIT
BlackRock Institutional Trust San Francisco, California $675B AUM 16.07% 1-Year Est. Return
BFA
BlackRock Fund Advisors San Francisco, California $542B AUM 18.13% 1-Year Est. Return

Ninety One (UK)'s JAZZ Position: Q3 2016 in Review

Ninety One (UK) sold out of Jazz Pharmaceuticals (JAZZ) in Q3 2016, closing a stake of 169,769 shares — an estimated $24M sold.

Ninety One (UK) first reported a position in JAZZ in Q2 2013 and held it in 13 quarters. The position peaked at $38.7M in Q3 2014. 325 funds tracked by Wall St. Rank hold JAZZ as of Q3 2016.

  • Ninety One (UK) reported no remaining Jazz Pharmaceuticals position as of Q3 2016 after selling out during the quarter.
  • Ninety One (UK) sold 169,769 Jazz Pharmaceuticals shares in Q3 2016, an estimated $24M.
  • Ninety One (UK) first reported a position in Jazz Pharmaceuticals in Q2 2013 and held it in 13 quarters.
  • Ninety One (UK)'s Jazz Pharmaceuticals position peaked at $38.7M in Q3 2014.
  • 325 funds tracked by Wall St. Rank held Jazz Pharmaceuticals as of Q3 2016.

Based on Ninety One (UK)'s 13F filing for Q3 2016, filed 14 Nov 2016.